Epidemiological Features and Predictors of Mortality in Patients with COVID-19 with and without Underlying Hypertension.

IF 1.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Hypertension Pub Date : 2021-10-19 eCollection Date: 2021-01-01 DOI:10.1155/2021/7427500

Leila Moftakhar, Elahe Piraee, Mohammad Mohammadi Abnavi, Parisa Moftakhar, Habibollah Azarbakhsh, Aliasghar Valipour

{"title":"Epidemiological Features and Predictors of Mortality in Patients with COVID-19 with and without Underlying Hypertension.","authors":"Leila Moftakhar, Elahe Piraee, Mohammad Mohammadi Abnavi, Parisa Moftakhar, Habibollah Azarbakhsh, Aliasghar Valipour","doi":"10.1155/2021/7427500","DOIUrl":null,"url":null,"abstract":"Backgrounds: Individuals with hypertension are at higher risk of COVID-19 infection and related mortality. This study was carried out to assess the epidemiological features and predictors of mortality in patients with COVID-19 with hypertension.Methods: In this retrospective study, the epidemiological characteristics of two groups of patients with COVID-19 with hypertension (1927) and without hypertension (39030) were compared. Chi-square test was applied to evaluate the differences between qualitative variables in two study groups. Logistic regression was also used to determine predictors of mortality in patients with COVID-19 and in patients with COVID-19 with hypertension.Results: The prevalence of hypertension in patients with COVID-19 was 4.7%, and 24.37% of COVID-19 related deaths occurred in these individuals. The average age of hypertension and nonhypertension patients was 61 and 37 years, respectively. Fever, cough, headache, anorexia, fatigue, and comorbid diseases, such as cardiovascular disease, chronic lung and kidney disease, diabetes, immunodeficiency disease, and thyroid disease, were significantly more frequent in people with hypertension than those without hypertension. The chances of mortality in patient with COVID-19 were 1.8 times higher in individuals with dyspnea, 1.25 in individuals with fever, 1.33 in individuals with cough, 3.6 in patients with hypertension, 2.21 in diabetics, and 2.2 in individuals with cardiovascular disease. Also, individuals with COVID-19 with hypertension that had dyspnea, immunodeficiency, and cardiovascular disease were at higher risk of mortality.Conclusion: Hypertension is a serious threat to patients with COVID-19. Therefore, in order to control these patients more precisely and reduce mortality in them, it is extremely important to develop prevention and treatment strategies.","PeriodicalId":14132,"journal":{"name":"International Journal of Hypertension","volume":"2021 ","pages":"7427500"},"PeriodicalIF":1.9000,"publicationDate":"2021-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526257/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2021/7427500","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Backgrounds: Individuals with hypertension are at higher risk of COVID-19 infection and related mortality. This study was carried out to assess the epidemiological features and predictors of mortality in patients with COVID-19 with hypertension.

Methods: In this retrospective study, the epidemiological characteristics of two groups of patients with COVID-19 with hypertension (1927) and without hypertension (39030) were compared. Chi-square test was applied to evaluate the differences between qualitative variables in two study groups. Logistic regression was also used to determine predictors of mortality in patients with COVID-19 and in patients with COVID-19 with hypertension.

Results: The prevalence of hypertension in patients with COVID-19 was 4.7%, and 24.37% of COVID-19 related deaths occurred in these individuals. The average age of hypertension and nonhypertension patients was 61 and 37 years, respectively. Fever, cough, headache, anorexia, fatigue, and comorbid diseases, such as cardiovascular disease, chronic lung and kidney disease, diabetes, immunodeficiency disease, and thyroid disease, were significantly more frequent in people with hypertension than those without hypertension. The chances of mortality in patient with COVID-19 were 1.8 times higher in individuals with dyspnea, 1.25 in individuals with fever, 1.33 in individuals with cough, 3.6 in patients with hypertension, 2.21 in diabetics, and 2.2 in individuals with cardiovascular disease. Also, individuals with COVID-19 with hypertension that had dyspnea, immunodeficiency, and cardiovascular disease were at higher risk of mortality.

Conclusion: Hypertension is a serious threat to patients with COVID-19. Therefore, in order to control these patients more precisely and reduce mortality in them, it is extremely important to develop prevention and treatment strategies.

查看原文本刊更多论文

伴有或不伴有高血压的 COVID-19 患者的流行病学特征和死亡率预测因素。

背景：高血压患者感染COVID-19的风险较高，相关死亡率也较高。本研究旨在评估伴有高血压的 COVID-19 患者的流行病学特征和死亡率预测因素：在这项回顾性研究中，对两组 COVID-19 患者的流行病学特征进行了比较，前者有高血压（1927 例），后者无高血压（39030 例）。采用卡方检验来评估两组研究中定性变量之间的差异。此外，还采用逻辑回归法确定了 COVID-19 患者和 COVID-19 伴有高血压患者的死亡率预测因素：结果：COVID-19 患者的高血压患病率为 4.7%，24.37% 的 COVID-19 相关死亡发生在这些人身上。高血压和非高血压患者的平均年龄分别为 61 岁和 37 岁。高血压患者的发热、咳嗽、头痛、厌食、乏力以及合并疾病（如心血管疾病、慢性肺病和肾病、糖尿病、免疫缺陷病和甲状腺疾病）发生率明显高于非高血压患者。COVID-19 患者的死亡几率分别是：呼吸困难患者的 1.8 倍、发烧患者的 1.25 倍、咳嗽患者的 1.33 倍、高血压患者的 3.6 倍、糖尿病患者的 2.21 倍和心血管疾病患者的 2.2 倍。此外，患有 COVID-19 并伴有呼吸困难、免疫缺陷和心血管疾病的高血压患者的死亡风险更高：结论：高血压对 COVID-19 患者构成严重威胁。结论：高血压对 COVID-19 患者构成严重威胁，因此，为了更精确地控制这些患者并降低其死亡率，制定预防和治疗策略极为重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hypertension Medicine-Internal Medicine

CiteScore

4.00

自引率

5.30%

发文量

期刊介绍： International Journal of Hypertension is a peer-reviewed, Open Access journal that provides a forum for clinicians and basic scientists interested in blood pressure regulation and pathophysiology, as well as treatment and prevention of hypertension. The journal publishes original research articles, review articles, and clinical studies on the etiology and risk factors of hypertension, with a special focus on vascular biology, epidemiology, pediatric hypertension, and hypertensive nephropathy.